Sign in Subscribe
Coronaviruses

Inferior Immune Responses to COVID-19 Vaccination in Solid Organ Transplant Recipients

Strategic Insights

— 1 min read

Researchers from Copenhagen University Hospital have published a new study examining the development of anti-receptor-binding domain (RBD) immunoglobulin G (IgG) after two doses of BNT162b2 in solid organ transplant (SOT) recipients and immunocompetent controls. The study found that immune responses to BNT162b2 are inferior in SOT recipients compared to healthy controls, with lower anti-RBD IgG concentrations and neutralizing capacities at all time points. This inferior vaccine response may have significant clinical implications, warranting further studies to determine the impact on disease severity and prevention.

Key Takeaways:

  • The study examined the development of anti-RBD IgG after two doses of BNT162b2 in 200 SOT recipients and 200 matched healthy controls.
  • Anti-RBD IgG concentrations increased in SOT recipients from first to second dose (1.14 AU/ml to 11.97 AU/ml), but declined to 55.85 AU/ml after six months.
  • At all time points, anti-RBD IgG was lower in SOT recipients than in controls.
  • Fewer SOT recipients than controls had a cellular response after six months (13.1% vs. 59.4%).
  • The study suggests that immune responses to BNT162b2 are inferior in SOT recipients compared to healthy controls, with implications for vaccine efficacy.

Statistics:

  • 200 SOT recipients and 200 matched healthy controls were examined in the study.
  • Anti-RBD IgG concentrations increased from 1.14 AU/ml to 11.97 AU/ml in SOT recipients after the second dose.
  • Anti-RBD IgG concentrations declined to 55.85 AU/ml in SOT recipients after six months.
  • 13.1% of SOT recipients displayed a cellular response after six months, compared to 59.4% of controls.

Sources:

  • Frontiers in Immunology. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls. 2022; 13.
  • NewsRx. Copenhagen University Hospital Researchers Have Provided New Study Findings on COVID-19 (Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls). Medical Letter on the CDC & FDA. March 13, 2022.

Read more